19 November 2026 in American Journal of Veterinary Research
Objective: To evaluate the efficacy of an extended-release formulation of buprenorphine HCl (XR-Bup) using objective gait analysis in a canine stifle arthrotomy model. We hypothesized that a single SC injection of XR-Bup would reduce postoperative pain and improve limb function. Methods: In a randomized, blinded, placebo-controlled crossover study design, 8 purpose-bred Beagles underwent 2 unilateral stifle arthrotomies, randomized to XR-Bup for 1 procedure and placebo for the other, separated by a washout period. Kinetic and static ground reaction force data were collected at baseline (pretreatment) and multiple time points up to 72 hours after arthrotomy. Symmetry indices were calculated for ground reaction force variables and compared between groups using a repeated-measures analysis. Results: Overall, symmetry indices of static body weight distribution (%BW distrib ) showed significantly greater limb use symmetry following XR-Bup compared to placebo. There was significant time and treatment interaction ( P = .025) for %BW distrib to the operated limb, with %BW distrib approaching baseline levels more quickly when treated with XR-Bup. Similarly, kinetic variables demonstrated higher limb use in the XR-Bup group, although the treatment effects were not significant. All dogs experienced nausea and hyporexia/anorexia after XR-Bup over 72 hours. Vomiting occurred in 6 of 9 and regurgitation was observed in 8 of 9 arthrotomy cases. Conclusions: XR-Bup treatment was associated with greater limb usage (static and dynamic) at all time points, with data indicating effective pain alleviation in a small cohort of dogs. Clinical Relevance: Although Ethiqa XR may be an alternative option for postoperative pain control, its clinical utility at the dose evaluated in this study may be limited by the occurrence of adverse events.